Research programme: HIV integrase inhibitors - Novita Healthcare

Drug Profile

Research programme: HIV integrase inhibitors - Novita Healthcare

Alternative Names: AVX 15567

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Avexa
  • Developer Novita Healthcare
  • Class Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 17 Apr 2014 Preclinical development is ongoing in Australia
  • 27 Apr 2012 Preclinical development is ongoing in Australia
  • 14 Jul 2010 HIV integrase inhibitors licensed to the Shanghai Institute of Organic Chemistry in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top